{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:48:22Z","timestamp":1740152902673,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843001805","843001805"],"award-info":[{"award-number":["843001805","843001805"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aim of surgery for advanced-stage ovarian cancer is a complete cytoreduction, because this is the most important independent prognostic factor for prolonged survival. Yet this can be difficult to achieve when there are micrometastases on the intestinal mesentery or intestines. The PlasmaJet device is an instrument to remove these micrometastases, but little is known about the depth of damage in human tissue compared to electrocoagulation devices.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A prospective study was performed for the ex-vivo comparison of the histological depth of thermal damage of neutral argon plasma (PlasmaJet\u00ae) and electrocoagulation devices, in a series of 106 histological slides of 17 advanced-stage ovarian cancer patients. Depending on the tissue types resected during complete cytoreductive surgery, samples were collected from reproductive organs (uterus, ovaries), intestines (ileum, colon, rectum) and omentum, intestinal mesentery and peritoneum.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Average thermal damage depth was 0.15\u00a0mm (range 0.03\u20130.60\u00a0mm) after use of neutral argon plasma and 0.33\u00a0mm (range 0.08\u20131.80\u00a0mm) after use of electrocoagulation (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Greater disruption of the tissue surface was often observed after electrocoagulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our case series suggests that the use of neutral argon plasma during cytoreductive surgery produces significantly less thermal damage than electrocoagulation treatment. It is therefore considered a thermally safe alternative, aiding in the achievement of cytoreductive surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-022-01070-5","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T07:03:04Z","timestamp":1672297384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series"],"prefix":"10.1186","volume":"15","author":[{"given":"Gatske M.","family":"Nieuwenhuyzen-de Boer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick J.","family":"van de Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia C.","family":"Ewing-Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleen J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7\u201334.","journal-title":"CA Cancer J Clin"},{"doi-asserted-by":"crossref","unstructured":"Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019.","key":"1070_CR2","DOI":"10.1136\/ijgc-2019-000308"},{"key":"1070_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","volume":"130","author":"LM Landrum","year":"2013","unstructured":"Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic Oncology Group study. Gynecol Oncol. 2013;130:12\u20138.","journal-title":"Gynecol Oncol"},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ygyno.2006.05.023","volume":"103","author":"EL Eisenhauer","year":"2006","unstructured":"Eisenhauer EL, D\u2019Angelica MI, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Barakat RR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol. 2006;103:871\u20137.","journal-title":"Gynecol Oncol"},{"key":"1070_CR5","doi-asserted-by":"publisher","first-page":"e39415","DOI":"10.1371\/journal.pone.0039415","volume":"7","author":"A Rafii","year":"2012","unstructured":"Rafii A, Stoeckle E, Jean-Laurent M, Ferron G, Morice P, Houvenaeghel G, et al. Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS ONE. 2012;7:e39415.","journal-title":"PLoS ONE"},{"key":"1070_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13048-019-0545-x","volume":"12","author":"GM Nieuwenhuyzen-de Boer","year":"2019","unstructured":"Nieuwenhuyzen-de Boer GM, van der Kooy J, van Beekhuizen HJ. Effectiveness and safety of the PlasmaJet\u00ae device in advanced stage ovarian carcinoma: a systematic review. J Ovarian Res. 2019;12:71.","journal-title":"J Ovarian Res"},{"key":"1070_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejogrb.2017.02.004","volume":"211","author":"N Bourdel","year":"2017","unstructured":"Bourdel N, Chauvet P, Roman H, Pereira B, Somcutian O, Dechelotte PJ, et al. Comparison between resection, bipolar coagulation and plasmajet(R): a preliminary animal study. Eur J Obstet Gynecol Reprod Biol. 2017;211:127\u201333.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1070_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00404-012-2302-x","volume":"286","author":"S Deb","year":"2012","unstructured":"Deb S, Sahu B, Deen S, Newman C, Powell M. Comparison of tissue effects quantified histologically between PlasmaJet coagulator and Helica thermal coagulator. Arch Gynecol Obstet. 2012;286:399\u2013402.","journal-title":"Arch Gynecol Obstet"},{"key":"1070_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/IGC.0000000000000849","volume":"27","author":"EJ Tanner","year":"2017","unstructured":"Tanner EJ, Dun E, Sonoda Y, Olawaiye AB, Chi DS. A comparison of thermal plasma energy versus argon Beam Coagulator-Induced Intestinal Injury after vaporization in a Porcine Model. Int J Gynecol Cancer. 2017;27:177\u201382.","journal-title":"Int J Gynecol Cancer"},{"key":"1070_CR10","doi-asserted-by":"publisher","first-page":"1853-6 e1","DOI":"10.1016\/j.fertnstert.2010.11.038","volume":"95","author":"H Roman","year":"2011","unstructured":"Roman H, Pura I, Tarta O, Mokdad C, Auber M, Bourdel N, et al. Vaporization of ovarian endometrioma using plasma energy: histologic findings of a pilot study. Fertil Steril. 2011;95:1853-6 e1\u20134.","journal-title":"Fertil Steril"},{"key":"1070_CR11","first-page":"1326","volume":"20","author":"Y Sonoda","year":"2010","unstructured":"Sonoda Y, Olvera N, Chi DS, Brown CL, Abu-Rustum NR, Levine DA. Pathologic analysis of ex vivo plasma energy tumor destruction in patients with ovarian or peritoneal cancer. Int J Gynecol Cancer. 2010;20:1326\u201330.","journal-title":"Int J Gynecol Cancer"},{"key":"1070_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12885-019-5275-3","volume":"19","author":"GM Nieuwenhuyzen-de Boer","year":"2019","unstructured":"Nieuwenhuyzen-de Boer GM, Hofhuis W, Reesink-Peters N, Ewing-Graham PC, Schoots IG, Beltman JJ, et al. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands. BMC Cancer. 2019;19:58.","journal-title":"BMC Cancer"},{"key":"1070_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med"},{"key":"1070_CR14","doi-asserted-by":"publisher","first-page":"1853-U447","DOI":"10.1016\/j.fertnstert.2010.11.038","volume":"95","author":"H Roman","year":"2011","unstructured":"Roman H, Pura I, Tarta O, Mokdad C, Auber M, Bourdel N, et al. Vaporization of ovarian endometrioma using plasma energy: histologic findings of a pilot study. Fertil Steril. 2011;95:1853-U447.","journal-title":"Fertil Steril"},{"key":"1070_CR15","first-page":"1022","volume":"24","author":"TK Madhuri","year":"2014","unstructured":"Madhuri TK, Haagsma BEN, Williams P, Tailor A, Butler-Manuel SA. Pathologic analysis of tissue Destruction with neutral argon plasma. Int J Gynecol Cancer. 2014;24:1022\u20133.","journal-title":"Int J Gynecol Cancer"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41416-020-01035-9","volume":"123","author":"DL Phelps","year":"2020","unstructured":"Phelps DL, Saso S, Ghaem-Maghami S. Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies. Brit J Cancer. 2020;123:1471\u20133.","journal-title":"Brit J Cancer"},{"key":"1070_CR17","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1245\/s10434-022-11763-2","volume":"29","author":"GM Nieuwenhuyzen-de Boer","year":"2022","unstructured":"Nieuwenhuyzen-de Boer GM, Hofhuis W, Reesink-Peters N, Willemsen S, Boere IA, Schoots IG, et al. Adjuvant use of PlasmaJet device during cytoreductive surgery for Advanced-Stage Ovarian Cancer: results of the PlaComOv-study, a Randomized Controlled Trial in the Netherlands. Ann Surg Oncol. 2022;29:4833\u201343.","journal-title":"Ann Surg Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-022-01070-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T07:06:35Z","timestamp":1672297595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-022-01070-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1186\/s13048-022-01070-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is carried out according to the standards outlined in the Declaration of Helsinki. Ethics committee approval has been granted. All procedures involving patients have been approved by the Medical Ethical Committee of Erasmus Medical Centre Rotterdam in the Netherlands (trial protocol version 3.0 d.d. 20th November 2017, NL62035.078.17). Registered in the Netherlands Trial Register, NTR 6624, NL62035.078.17.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing\u00a0 interests"}}],"article-number":"140"}}